Show results for
Refine by
Therapeutics Announces Lead Candidate Equipment & Supplies
38 equipment items found
by:Sibylla Biotech S.p.A. based inVerona, ITALY
What makes us unique is the power of our computational platform, which enables us to reconstruct the series of conformational rearrangements underlying the process of protein folding at an atomistic level of ...
by:Ainovo Biotech Inc. based inSacramento, CALIFORNIA (USA)
AlOptimus™ brings to bear AINovo's proprietary machine learning algorithms on our highly curated datasets to enhance the therapeutic profiles of drug candidates. The AlOptimus platform optimizes validated candidates to derisk development and inform clinical ...
Manufactured by:ZIND Verfahrenstechnik based inMainz, GERMANY
At pilot stage, the primary membrane candidate has been chosen, as process parameters. Typically at this stage, the production method is being verified and production materials produced for toxicology or pre-clinical trials and predictable scalability is imperative. In order to facilitate the manufacturing life cycle of a successful therapeutic candidate, cGMP manufacturing needs to begin at ...
Manufactured by:VECT-HORUS based inMARSEILLE, FRANCE
Vect-Horus has developed its “VECTrans®” breakthrough technology platform with the objective of making the ‘undruggable’ druggable by overcoming challenges of the BBB, and more generally biological barriers. VECTrans® is based on the specific design and optimization of ‘molecular vectors’ that, once conjugated to a payload, enable its delivery to target ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
elociT™ is our unique mouse technology for producing fully human therapeutic T-cell receptors (TCR) against tumor and viral antigens. Regeneron uses this technology as part of its efforts to discover and develop novel immuno-oncology therapeutic candidates, including combination approaches and to assist our collaborators in producing fully human therapeutic ...
Manufactured by:Rocket Pharmaceuticals, Inc. based inCranbury, NEW JERSEY (USA)
The LVV platform is ideal for modifying hematopoietic stem cells (HSCs) to address disorders affecting the bone marrow. The LVV transduction process occurs ex vivo (outside the body), which ensures that the gene has been properly integrated before the therapy is given to the patient. The process involves collection and isolation of a patient’s hematopoietic stem cells ...
Manufactured by:Rocket Pharmaceuticals, Inc. based inCranbury, NEW JERSEY (USA)
The LVV platform is ideal for modifying hematopoietic stem cells (HSCs) to address disorders affecting the bone marrow. The LVV transduction process occurs ex vivo (outside the body), which ensures that the gene has been properly integrated before the therapy is given to the patient. The process involves collection and isolation of a patient’s hematopoietic stem cells ...
by:Redbiotec AG based inSchlieren, SWITZERLAND
Redbiotec specializes in developing high-quality vaccines to fight difficult diseases. After successfully spinning out the CMV vaccine program that was acquired by Pfizer, Redbiotec is currently developing HSV-2 therapeutic vaccine ...
Manufactured by:Codexis, Inc. based inRedwood City, CALIFORNIA (USA)
Achieve exceptional IVT results with Codex® HiCap RNA Polymerase, a co-transcriptional capping RNA polymerase that has been uniquely engineered to produce synthetic mRNA at high yield and low ...
Manufactured by:Ocugen, Inc. based inMalvern, PENNSYLVANIA (USA)
OCU410 (AAV-RORA) is a modifier gene therapy product candidate being developed for the treatment of dry age-related macular degeneration (Dry AMD). OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene. Various genes associated with AMD are regulated by RORA. The RORA protein plays an important role in lipid metabolism and demonstrates ...
by:Sutro Biopharma Inc. based inSouth San Francisco, CALIFORNIA (USA)
Conventional methods for expressing proteins utilize cell lines originating from bacteria, yeast, insects, plants, or mammals. Because these methods require intact, functioning cells, the biochemical and biophysical parameters under which proteins are produced using these methods are inherently limited, often failing to produce many proteins and biologics. Using cell-based expression systems to ...
Manufactured by:Catalent, Inc based inSomerset, NEW JERSEY (USA)
GPEx cell line development technology is a proven technology that generates high-performance, highly stable, production cell lines. Virtually any cDNA (mAb and multigenic applications) can be inserted into cells. To date, over 600 different mAb and mAb fusions and over 160+ different recombinant proteins have been produced using the GPEx system, with 160+ clinical trials utilizing therapeutic ...
Manufactured by:Mimetas B.V. based inLeiden, NETHERLANDS
Profiling and screening of your compounds with a high throughput barrier integrity assay on our established Caco-2 intestinal model. OrganoServices are available for multiple assays to allow compound profiling and/or screening in human-relevant, complex 3D tissue models. When developing new drugs, it is critical to understand the permeability, absorption, and transport mechanisms in relevant ...
Manufactured by:Ncardia Services B.V. based inLeiden, NETHERLANDS
Disturbances in calcium signaling are associated with many neurodegenerative diseases and cardiomyopathies. Fluorescence-based assays with iPSC-derived cardiac and neuronal models can be used to monitor short and long-term drug-induced changes on calcium transients. Our scientists develop the most optimal calcium transient assay for each project and can scale it up for high-throughput screening, ...
Manufactured by:Newcells Biotech Limited based inNewcastle Upon Tyne, UNITED KINGDOM
Human lung fibroblast model to test the efficacy of anti-fibrotic agents in vitro. Newcells human primary lung fibroblast model is the basis of our FMT assay to evaluate anti-fibrotic therapies in vitro at high throughput. The assay replicates extracellular matrix deposition (ECM) observed in vivo when lung fibroblast injury leads to activation and proliferation. Following injury, pulmonary ...
by:Intellia Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
The first patient was dosed with our investigational genome editing treatment for transthyretin (ATTR) amyloidosis in November 2020. Our modular approach enables us to optimize the power and versatility of the CRISPR/Cas9 technology and, importantly, allows us to rapidly develop therapeutics for numerous diseases that currently have limited treatment ...
Manufactured by:Ncardia Services B.V. based inLeiden, NETHERLANDS
Astrocytes are essential players in neurodegenerative disease progression providing a valuable tool for drug discovery and disease modeling. Human iPSC-derived astrocytes generated with our standardized process express key identity markers and support co-culture with human iPSC-derived neurons. Our team can manufacture astrocytes at scale from the iPSC that best fits your project or work with ...
Manufactured by:Lung Therapeutics, Inc. based inAustin, TEXAS (USA)
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by progressive tissue scarring that prevents proper lung function. LTI-03 operates through a novel mechanism of action (MOA) that is unlike any MOA seen in the therapeutic candidates of today. By targeting healthy epithelial cells, LTI-03 promotes the protection of lung epithelium while inhibiting fibroblast growth and ...
Manufactured by:BlueWillow Biologics based inAnn Arbor, MICHIGAN (USA)
Herpes simplex virus-2 (HSV-2) is the leading cause of genital herpes, a sexually transmitted disease affecting over 500 million people worldwide. BlueWillow’s intranasal nanoemulsion (NE) vaccine is uniquely suited to offer protection against this painful and distressing affliction, through its ability to elicit both a systemic and mucosal immune ...
Manufactured by:Regenerative Medical Solutions Inc. (RMS) based inMadison, WISCONSIN (USA)
We are developing autologous and allogeneic versions of ILC cellular therapeutic. In the case of autologous ILC cellular therapeutic we will convert the diabetes patients own cells into iPSC cells followed by differentiation of the patient derived iPSC into ILC using our patented and proprietary technology. These patient cell derived ILCs will then be surgically transplanted into the ...